Register

Agenda

Registration and Welcome
Registration Onsite
Chair’s Opening Remarks
Session 1: Perspectives from Pharma and Biotech Companies
Impurity profiling of drug products-impact from container closure system
Networking break
Session 2: E&L Study on Pharma Packaging
Networking Lunch
E&L study on ophthalmic pharmaceutical packaging materials
Session 3: E&L Study on Single Use Systems
E&L study for single-use systems based on risk assessment
  • Application of SUS in the field of biopharmaceutical
  • Introduction of the regulations and technical guidelines for the E&L risk assessment of SUS
  • E&L study process and key points for SUS
  • Research data and process validation services that suppliers can provide to users

Cuicui Zhu | Validation Center Manager, Hangzhou Cobetter
Extractables and leachables from single-use system in biopharma manufacturing process
Due to convenience, flexibility and cost reduction, single use system (SUS) has been widely used in the process development and commercial production of monoclonal antibody therapeutics. Applied in upstream cell culture, downstream drug substance purification and storage, as well as fill-finish bioprocess of drug product, SUS/single use component can introduce extractables and leachables (E&L). Those chemical entities can cause quality issues and pose to risks to the health of patients. Hence domestic and international regulations have more and more concern on E&L study in new drug applications (NDA) phase. A thorough summarization of E&L regulations and industrial guidelines will be presented in this report. E&L workflow and considerations in terms of information collection, risk assessment, extractable study, leachable study, and safety evaluation will be described in details.
Carol Cao | E&L Manager, Biology Analytical Development , Henlius
Theory and practice of using extractables data from SUS for extrapolation to PERLs
  • How to use the extractables data from supplier 
  • How to perform extractables assessment for SUS
  • Sartorius Extractables Simulator theory and practice

Hovery Yin | Confidence® Validation Services, Project Manager E&L, Sartorius
Registration and Welcome
Registration Onsite
Chair’s Opening Remarks
Session 4: Risk Assessment and Risk Management on E&L
Proposed changes to the ISO 10993-17 standard
Leachables risk management
  • Why is it important to have a framework for leachables risk management?
  • The rationale for and scope of the ELSIE risk management papers
  • Description of key aspects of the risk management framework, such as materials screening and selection, risk assessment, chemical and safety risk control and lifecycle
  • Update on development of the ELSIE Knowledge Base (data sharing platform)

Lee M. Nagao, Ph.D. | Senior Director, Science, Regulation & Policy, ELSIE
Application of the Threshold of Toxicological Concern (TTC) to biological evaluation of medical devices - case sharing
Session 5: E&L Study on Medical Devices
Networking break
ISO 18562 experience sharing of respiratory medical devices
Lunch break
Perspective from medical device company on E&L study
Session 6: Challenges and Technical Advances on E&L Analysis
Chemistry inputs to toxicological risk assessment; analytical uncertainty and uncertainty factors
The E&L responsibility of the analytical chemist to is to supply accurate, true and complete data to the toxicologist for safety risk assessment.  Critical activities performed by the analytical chemist include discovering all the relevant compounds above a defined safety-driven threshold, establishing the true identity of the discovered compounds and accurately quantifying the discovered and identified compounds.  In the ideal world, these activities are achieved effectively and reproducibly.  In the real world of challenging thresholds, low concentration analytes, and difficult analytical matrices, uncertainty in the analytical outcome is the rule (rather than the exception) and E&L profiles are imprecise and can vary within labs and across labs.
In this presentation, sources of analytical variation are considered and the presenter provides practical insights into the management and control of the various sources of the variation, including the proper use of uncertainty factors. 
 
Dennis Jenke | Chief Executive Scientist, Triad Scientific Solutions, UK
Networking break
Session 7: E&L Study for Transdermal Patches
Extractables and leachables testing and assessments for transdermal patches
The delivery route of transdermal patches is becoming more and more popular, and the effect of the delivered drugs can be localized, reducing or even eliminating systemic side effects. Transdermal patches are composed of various types of polymers, which are bonded together by an adhesive layer or adhesive. The leachables from the transdermal backing membrane, release liner, storage bag may
cause potential risk to patient safety.
"Transdermal and Topical Delivery Systems-Product Development and Quality Considerations Guidance for Industry" formulated by FDA (2019), "Technical Guidelines for Pharmaceutical Research on Transdermal Patches of Chemical Generic Drugs (Trial)" formulated by the Center for Drug Evaluation of China National Medical Products Administration (2020), both require an evaluation of extractables and
leachables. The extraction test should be carried out under severe conditions with a variety of solvents in a variety of polar ranges to maximize the content of extractables and determine as many potential extracts as possible. The conditions of the leachable study should be as close as possible to the "worst case" skin clinical conditions (for example, sweating during strenuous exercise), choosing the appropriate solvent/solution selection (for example, salt concentration), temperature, degree of
agitation, and exposure to solvents The duration and so on.
This speech will formulate strategies for transdermal patches and their packaging systems, focusing on choosing different extraction conditions, using different test methods to determine potential extractables in transdermal patches, and introducing methods for evaluating actual extractables, monitoring the leachables by using validated analytical method.
Yi Zhang | Laboratory Director, Guangzhou Brunslab Co., Ltd